India Stock News; BSE Falls 44 Points, but off Session Lows: SBI, ICICI, Reliance, Coal India, Kingfisher Airlines

India Stock News; BSE Falls 44 Points, but off Session Lows: SBI, ICICI, Reliance, Coal India, Kingfisher Airlines

POINT ROBERTS - April 11, 2012 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues the following market and economic commentary for investors following investing in India.

Indian stocks ended lower on Wednesday, but off session lows on hopes that the tsunami is unlikely to hit India. Stocks were under pressure earlier in the session after 8.6 magnitude earthquake hit in Aceh (Indonesia ), which dragged the Bombay Stock Exchange down 100 points in the afternoon session.
The market gapped down, but it bounced back, from a positive opening from European markets. However, the tsunami caution in Tamil Nadu and Andhra Pradesh etc post earthquake pulled the major indices lower once again. The BSE benchmark slid 44.44 points or 0.26%, to close at 17,199.40 and the NSE benchmark lost 16.75 points to 5,226.85.

A Tsunami warning was issued in 28 countries including Indonesia, Australia, Singapore, Thailand, India and Maldives. Tremors felt in Kolkata, Chennai, Bangalore, Patna and some other parts of countries.
Following an earthquake in Indonesia, shares of India Cements slumped about 8% as the company has several coal sourcing contract in Indonesia. Power companies like Lanco Infratech, GVK Power and JSW Energy were under pressure as well and fell between 2-4% as such companies have minings in Indonesia.
Reliance Industries and Bharti Airtel were the top losers on the BSE and lost 1.40% and 2.30% respectively.
Metal stocks slumped following a 4% fall in LME copper yesterday with Jindal Steel, Sesa Goa and Sterlite Industries lost 2-3%.

Banking stocks were among few gainers with Bankex gained as much as 1% intraday, which closed up just 0.2%. Lenders HDFC Bank, Axis Bank and State Bank of India saw solid gains. Kotak Mahindra Bank climbed 2%.
The aviation sector was the top performer and several companies like Jet Airways, Kingfisher Airlines, SpiceJet ended higher over 5% on reports that the government is considering to allow 49% FDI in air carriers.

Kingfisher Airlines, which had been under selling pressure recent on financial turmoil, rose over 6% on reports that Mukesh Ambani group's flagship company Reliance Industries is planning to but stake in the company. As part of the deal, Reliance may also get Mangalore Chemicals, in which the UB group has over 30% stake.
Coal India Ltd ended lower by 0.10% on the leaked draft report of the Comptroller and Auditor General of India (CAG) stated that the company overstated its manpower productivity for five years between April 2006 and March 2011.
GMR Infrastructure rose about 1% the company has finalized plans to raise debt of 54 billion rupees to finance its recently won highway project between Rajasthan and Gujarat.
Learn more about Investing in India at Invsestorideas.com

http://www.investorideas.com/ISM/ and http://www.indiastockmarket.com/

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas


Get Free investor news and stock alerts- Sign Up:

Join Investor Ideas Get 13 of the best stock directories online;Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join Today


Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

Source – Investorideas.com
800-665-0411

Indian Stocks Falls weighed by Technology & Banking Stocks

Indian Stocks Falls weigh by Technology & Banking Stocks

POINT ROBERTS, August 24, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues the following market and economic commentary for investors following investing in India.

Indian stocks closed sharply lower after two days of rallying , as shares of technology companies and automakers continued their selling on global debt crisis. Increased chances of strict monetary policy also added further selling in the stock markets.

The main 30-share BSE index fell 213.49 or 1.30% to closed at 16,284.98, 90% of the indices contributors ended lower. The S&P CNX Nifty also lost 60 points or 1.21% to closed at 4,888.90 after hitting day’s high of 4,962.40 and low of 4,875.30.

On BSE, 1,528 shares ended lower and 1,313 shares jumped.

However, mid -cap and small -cap stocks relatively outperformed the broader markets with both the indices ended lower by around 0.50% each.

Coal India Ltd. was the biggest loser with the stock slumping as much 4.61% on concern that t 22 of its mines face closure over environmental concerns in eastern India, which could cut its output by 40,000 tonnes a day.

Among the auto shares, MARUTI SUZUKI lost 3.77% to 1,114.5 rupees, TATA MOTORS slumped 3.70% and TVS MOTOR declined 2.03%.

In the technology space, INFOSYS LTD lost 1.14% to close at 2,250.90 rupees, HCL INFOSYS fell 3.05% to 66.80 rupees.

Banking stocks also slid with SBI falling 3.58% to 1,989.75 rupees, BANK OF INDIA lost 3.77% to 307.50 rupees. AXIS BANK slid after rising in yesterday’s session and lost 3.12% to 1,049.70 rupees.

Bharat Heavy Electricals also lost 0.57% after analyst at HSBC reduced its price target on the stock to 1,590 rupees from 1,850 rupees.


Learn more about Investing in India at Invsestorideas.com
http://www.investorideas.com/ISM/ and www.Indiastockmarket.com


Investorideas.com Free Investor Tools;

Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp

Join Investor Ideas – Become a Member
Research renewable energy stocks, gold stocks, water stocks, oil and gas and more with the largest stock directories online for investors
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including renewable energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/


About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas


Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp


For Additional Information and or interest in becoming a content /revenue partner:

800-665-0411 – cvanzant@investorideas.com
Source – Investorideas.com

Biodefense Stocks; Aethlon Medical (OTCBB:AEMD) Discusses Device Opportunity To Treat Sepsis and Bioterror Threats

San Diego, CA, March 16, 2011 � Investorideas.com newswire; Biotech and biodefense stock news; Aethlon Medical Shareholder Letter Aethlon Medical, Inc., (OTCBB:AEMD) disclosed that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
Website: aethlonmedical.com

To our Shareholders:
As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats. This policy shift redefines the primary strategic objective of related government agencies to be the identification and support of innovative broad-spectrum countermeasures, technologies, and platforms. This is a considerable shift from the government�s previous focus of attempting to align a single drug or vaccine countermeasure with each pathogen threat. We remain convinced that our Hemopurifier� is the most advanced broad-spectrum countermeasure, technology, or platform.
Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier� as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. While the pursuit of government grants and contracts is not our primary focus, it is difficult to ignore a growing pipeline of new and evolving opportunities to advance our science with non-dilutive capital resources.
On February 8th, we were pleased to learn that the Defense Advanced Research Projects Agency (DARPA) released a broad agency announcement (BAA) entitled: �Dialysis Like Therapeutics� (DLT). The goal of the DLT program is to develop a portable device that removes �dirty� blood from the body, separates harmful agents, and returns �clean� blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device will be capable of removing at least 90% of unknown pathogens, toxins, and activated cells from a patient in one day. As stated in the BAA, targets for removal include viral pathogens referenced to include Hepatitis-C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza Bio-agents, Smallpox, and viral hemorrhagic fevers. As we have proven capabilities within the scope of this BAA, we plan to respond with a full proposal by April 1st.
If you are not familiar with DARPA, their mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use. Innovation sponsored by DARPA has resulted in groundbreaking discoveries and life changing advances such as the internet. DARPA envisions that the device developed under this BAA would save the lives of thousands of military patients each year.
If selected to participate in the DLT program, we would anticipate a multifaceted role that would involve teaming with other industry partners to advance our core Hemopurifier� as an innovative dialysis-like multi-use platform technology able to selectively target deleterious pathogens and toxins from the entire circulatory system. We would also seek expand the capabilities of our technology platform as the basis for a device targeting to reduce the presence of circulating factors that are precursors to sepsis. Our goal would be to reduce the occurrence of sepsis as post-sepsis treatment strategies to inhibit the inflammation process including the modulation of inflammatory cytokines have yet to be proven clinically beneficial. It is also possible that we could participate in the advancement of portable blood pump technology required under the BAA that would be deployed to treat wounded warfighters with extracorporeal device technologies including current and future iterations of our Hemopurifier� technology. Regardless of outcome, it is truly gratifying to witness therapeutic filtration being the focal point of a government contract opportunity. This is especially true when it comes from an agency as scientifically adept as DARPA. Once we complete our submission to DARPA, I will be back in touch with an update on other activities.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company�s ability to raise capital when needed, including obtaining government grants, the Company�s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company�s ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company�s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company�s Securities and Exchange Commission filings.
Disclaimer /Disclosure
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Visit the profile at Investorideas.com: http://www.investorideas.com/co/aemd/

Biotech Stocks; Aethlon Medical (OTCBB: AEMD) Receives FDA Approval to Export its Hemopurifier to India

Biotech Stocks; Aethlon Medical (OTCBB: AEMD) Receives FDA Approval to Export its Hemopurifier to India


Visit this company: http://www.aethlonmedical.com/


SAN DIEGO - March 8, 2011 (Investorideas.com Newswire) - Aethlon Medical, Inc. (OTC Bulletin Board:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Aethlon's request to export its Hemopurifier® medical device to India.



The FDA's approval was granted under Section 801 (e) of the Federal Food, Drug, and Cosmetic Act, as amended (the Act). Section 801 (e) of the Act covers class III medical devices, such as the Hemopurifier®, that have not yet received an approved Premarket Approval in the US by the FDA. Section 801 (e) applies to medical devices that are acceptable to the importing country and that are manufactured under the FDA's Good Manufacturing Practices.



"The granting of our export license by FDA represents a critical step in our strategy to initiate future commercialization of our Hemopurifier® in India," stated Jim Joyce, Aethlon Chairman and CEO.



Aethlon is currently conducting a clinical study entitled: "Use of the Aethlon Hemopurifier® in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy" at the Medicity Institute (Medicity) near Delhi, India. The Medicity is a $360 million multi-specialty medical institute recently established on a 43-acre campus to be a premier center of medical tourism in India. A clinical goal of the Aethlon-Medicity study will be to demonstrate that the Hemopurifier® is able to accelerate the benefit of HCV standard of care (SOC) drug regimens. Therapeutic filtration at the outset of SOC improves early virus reduction kinetics to levels associated with that of patients most likely to achieve a sustained viral response, which is the goal of HCV therapy. Additionally, lower quantities of HCV in circulation at the outset of SOC correlate with increased cure rates. Upon demonstration of treatment efficacy, Aethlon plans to commence commercialization of its Hemopurifier® in India.



About Aethlon Medical



At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.



Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.



Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.



As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:



Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.

Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.

Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.

Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.



In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.



Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.



Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.



Contacts:



James A. Joyce

Chairman, CEO

858.459.7800 x301

jj@aethlonmedical.com



John P. Salvador

Director, Communications & Investor Relations

858.459.7800 x307

jps@aethlonmedical.com



More Info:



Published at www.Investorideas.com - Global research by sectors



If you have any questions regarding information in this press release please contact the company listed in the press release.



Connect with Investorideas.com
Publish Your News - Send a release

Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Power of Ideas - How India is making it work

The Power of Ideas - Angel Investment Network in India
http://www.ideas.economictimes.com/1_Angel_Investment_Networks.aspx 

also contact Investorideas.com Marketplace and see how we are making investor ideas come to life!
http://www.investorideas.com/Marketplace/

1 Chennai Fund www.chennai.tie.org raghu.rajagopal@energeate.com Seed Funding for start ups in Tamil Nadu. Promoters include R. Ramaraj among others.

2 Indian Angel Network IAN Consultancy Services Pvt. Ltd.

B 8, Shopping Arcade



Hotel Surya Crowne Plaza



New Friends Colony



New Delhi 110 065.



Phone - +91 11 4162 8566



info@indianangelnetwork.com

Angel investors network with successful entrepreneurs and CEOs interested in investing in early stage businesses.

3 Mumbai Angels vimmla@mumbaiangels.com

www.mumbaiangels.com

Platform to start up and very early stage companies; helps in bringing them face to face with investors, mentoring, inputs on strategy.

4 TiE Entrepreneurship

Acceleration Program

3rd Floor, A Wing, Divyasree Chambers,

# 11, O'Shaugnessy Road,



Bangalore - 560 025.



Phone : (080) 41474567/68/69



Email: eap-program@tiebangalore.org

Ecosystem of Angels, Investors and VCs to provide Series A round of financing for Start ups.

5 Avendus Advisors Investor, Avendus IL&FS Financial Centre,

West Quadrant - 2nd Floor,



Bandra-Kurla Complex, Bandra (East)



Mumbai - 400 051



Phone: 91-22-6648-0050



Fax: 91-22-6648-0040



mumbai@avendus.com

Investment in IT Services, IT Enabled Services,

Pharmaceuticals and Healthcare, Media and



Consumer Products and Services.



6 Gesco Corporate Centre BT Limited

70 Nehru Place



New Delhi 110019



www.bt.com



Phone: +91 11 5211 9900



Fax:+91 11 5211 9901



arun@gmail.com

N A

7 Helion Ventures Pvt Ltd Helion Ventures Pvt Ltd

Tavant Technologies



First Floor, Pine Valley



Embassy Golflinks Business Park



Koramangala Intermediate Ring Road



Bangalore 560 071



Phone: +91 80 4018 3333



Fax: +91 80 4018 3456



www.helionvc.com



contact@helionvc.com

Investment in Technology and Services

8 Graycell Graycell No 17/4C, 17/9C

Chairman & CEO, July Systems 4th Floor Maruthi Chambers



Roopena Agrahara, Hosur Road



Bangalore 560068



Phone: +91-80-4110-JULY



Fax: +91-80-4110-1210



www.julysystems.com

N A

9 Gabriel Venture Partners Gabriel Venture Partners

350 Marine Parkway, Suite 200



Co- Founder, CTO Exodus Redwood Shores, CA 94065



CEO, NetScaler Phone:650.551.5000



Fax: 650.551.5001



Webinfo@GabrielVP.com





Seed Advisors Pvt. Ltd.



001, Turf Estate, Shakti Mills Lane,



Off. Dr. E. Moses Road, Mahalaxmi,



Mumbai 400011.



Phone:+91 22 24902201 – 04



Fax:+91 22 24902205



www.seedfund.in

Investment in Software, Systems, Technology, Internet,

Mobile, Digital Media, Disruptive Technologies



10 Jam Cracker Jamcracker Software Technologies

Pvt. Ltd., Maruthi Chambers, Towers - 1st Floor, 17/09 C, 17/4C. Rupena Agrahara, Hosur Road Bangalore 560 068.



Phone: +91 (0)80 66171717



Fax: +91 (0)80 66171723



www.jamcracker.com



info@jamcracker.com

Investment in research and development ventures in USA

and India



11 Inventus

Inventus Capital Partners

3000 Sand Hill Road,



Founder, Excelan Menlo Park, CA 94025





Seed Advisors Pvt. Ltd.



001, Turf Estate, Shakti Mills Lane,



Off. Dr. E. Moses Road, Mahalaxmi,



Mumbai 400011. India.



Phone:+91 22 24902201 – 04



Fax:+91 22 24902205

Investment in early stage technology companies

12 Brocade Communications Brocade Communications Systems Private Limited.,

Level 2, Raheja Centre Point



294 CST Road, Near Mumbai University



Off Bandra-Kurla Complex, Kalina,



Santacruz (East), Mumbai - 400098



Phone +91 22 6707 8605 / +91 22 6707



8Fa6x0:6 +91 22 6707 8711



E-mail: apac-info@brocade.com

Investment in storage Networking Start Ups

13 Jain Group of Institutions Jain Group of Institutions

No. 91/2, Dr A N KrishnaRao Road,



V V Puram, Bangalore - 560 004.



Phone: 080 26615246



info@jaingroup.info



www.jgi.ac.in

N A

14 Nadathur Holding and Investments Nadathur Holdings and Investments

Pvt. Ltd.,



# 278/23, 3rd Floor, 10th Main,



T.Mariappa Road, 2nd Block,



Jayanagar, Bangalore 560 011.



Phone: 91 80 41204336/37/38



Fax: 91 80 41204339



info@nadathur.com

Investment in knowledge based and innovation driven Indian ventures

15 Net Core Solution Netcore Solutions Pvt. Ltd

402, Peninsula Chambers, Peninsula Corporate Park, Ganpat Rao Kadam Marg, Lower Parel (West), Mumbai 400 013.



Phone: +91 (22) 6662 8000



www.emergic.com, www.emergic.org



rajeshjain@netcore.co.in





Investment in mobile, broad band and emerging technologies

16 Helion Helion Ventures Pvt Ltd

First Floor, Pine Valley



Embassy Golflinks Business Park



Koramangala Intermediate Ring Road



Bangalore 560 071



Phone: +91 80 4018 3333



Fax: +91 80 4018 3456



www.helionvc.com



contact@helionvc.com





N A

17 e4e India Corporate Office e4e India Corporate Office

Head, Wipro Divyashree Chambers, 3rd Floor, Langford Road



Bangalore 560025



Phone: +91 80 2212 0009



Fax: +91 80 2207 2186



www.e4e.com

N A

18 NEA-IndoUS Ventures NEA- IndoUS ventures

Ground Floor, Navigator



ITPB, Whitefield main road



Founder, Bangalore - 560066



Phone : 080 6616 9503



Fax: 080 6616 9506



neaiuvinfo@neaiuv.com



www.neaiuv.com

Early stage funding to new Indian ventures

19 Kuruvindum Phone: + 91 98410 47818

rahuldevgupta@gmail.com



www.kuruvindum.com

Chennai based early stage mentoring, angel and seed fund in Technology start ups

20 Tempus Capital sonal@tempuscapital.in Bangalore based angel investment firm

Investorideas.com - Green Stock News; USAID Selects Clenergen (CRGE.PK) as One of Its Top 12 Projects Approved for Equity Financing to Its Investment Partners in India

Investorideas.com - Green Stock News; USAID Selects Clenergen (CRGE.PK) as One of Its Top 12 Projects Approved for Equity Financing to Its Investment Partners in India

LONDON, ENGLAND - October 20, 2010 (www.investorideas.com renewable energy /green stocks) - Clenergen Corporation (Pinksheets:CRGE) today announced that USAID have sponsored Clenergen at its Investment Forum being held in Bombay on October 21, 2010. Twelve projects were selected for presentation to its Indian investment partners, a pool of 380 Investors. Over 50 major banks, 40 Venture Capital Private/Equity Groups and expert project proponents and Consultants will be attending the Forum
Clenergen Corporation has submitted four projects for $10 million of equity financing. The projects will create an additional 16MW/h of generating capacity at its two operational biomass power plants in Tamilnadu India, along with the acquisition of an existing 7.5MW/h biomass power plant in Karnataka, India. The company projects an operating capacity of 40Mw/h biomass power plants in India with estimated annual gross revenue of $40 million.

Commenting on the selection, Mark Quinn, Executive Chairman of Clenergen Corporation said "USAID's sponsorship of Clenergen's Indian projects to its investment partners is a prestigious recognition of our business model and illustrated the progress we have achieved in India over the past two years".

About Clenergen Corporation
Clenergen Corporation is a publicly-traded company with its common stock quoted on the Over-the-Counter-Bulletin Board (OTC-BB Symbol: CRGE.OB). Clenergen offers strategic clean energy generation and supply of biomass feedstock to address the requirement for renewable and sustainable supplies of electricity. Clenergen has developed a unique modular system for gasification and localized plantation management. Clenergen also plans to provide biomass feedstock for producing wood pellets for co firing with coal to produce low emission electricity.

Clenergen Corporation intends to use proprietary and mixed biomass feedstock to implement sustainable supplies of clean energy for regional, captive end users, remote islands, and mining companies and, through government- or privately-owned power grid systems, other end users, including private homes. The "Distributed Environmental Power System" marries significant proprietary advancements in plant science with proven long standing engineering technologies to achieve this goal. For further information on Clenergen Corporation and its products and services, go to: www.clenergen.com.

Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"). To the extent that any statements made in this press release contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expect," "plan," "will," "may," "anticipate," "believe," "should," "intend," "estimate," and variations of such words. Forward-looking statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, those risks and uncertainties contained in this press release and those identified in the periodic reports that the company files with the Securities and Exchange Commission (the "SEC") pursuant to the Exchange Act.

Contacts:
Clenergen CorporationJessica Hatfield0044 (0)207 739 00280044 (0)207 657 3275 (FAX)www.clenergen.com

Disclaimer/disclosure: The following news is paid for and /or published as information only for our readers. The info on CRGE.PK is a paid for submission paid for by a third party (fifteen hundred for one week of news /articles). Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investments involve risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Pink sheet disclaimer: http://www.pinksheets.com/otcguide/investors_protection.jsp

Visit this company: www.clenergen.com

Published at www.Investorideas.com - Global research by sectors

If you have any questions regarding information in this press release please contact the company listed in the press release.

Connect with Investorideas.com - http://www.twitter.com/Investorideas Publish Your News - Send a release - http://www.investorideas.com/News-Upload/

Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Water Stocks News; Indian Water Treatment company, VA Tech Wabag Spikes in Market Debut

Water Stocks News; Indian Water Treatment company, VA Tech Wabag Spikes in Market Debut

-as reported by eco- business

Water Treatment Company VA Tech Wabag Jumps 30% in Mumbai Trading Debut

India, October 13 - VA Tech Wabag Ltd., an Indian water treatment company, jumped as much as 30.4 percent in its Mumbai trading debut after receiving demand for 36 times the shares on sale in its initial public offering.
The stock, which started trading at 1,662 rupees, rose 397.95 rupees to 1,707.95 rupees at the 3:30 p.m. close in Mumbai. It rose as much as 37.9 percent to 1,806.8 rupees in intraday trading from the offer price of 1,310 rupees a share in an IPO last month

full story- http://www.eco-business.com/news/2010/oct/13/water-treatment-company-va-tech-wabag-jumps-30-mum/


More water stocks info and water stocks research resources for investors:
Visit the water stocks directory, one of the most comprehensive water stocks directory online- Publicly traded water companies on global stock exchanges: http://www.investorideas.com/Water-Stocks/Stock_List.asp


Investorideas.com and www.Water-Stocks.com are positioning to be a leading destination for cleantech investors researching the water space.
Water stocks- become a showcase water stock at www.investorideas.com and www.water-stocks.com for as little as $1000 month !